SynthesisBMC gastroenterology2014
The serotonin transporter gene polymorphism (5-HTTLPR) and irritable bowel syndrome: a meta-analysis of 25 studies.
Synthesis in BMC gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 3 syntheses or guidelines pooled it, 70 citations in OpenAlex.
- Risk factors for developing irritable bowel syndrome: systematic umbrella review of reviews.BMC medicine · 2025Pooled it
- Candidate single nucleotide polymorphisms of irritable bowel syndrome: a systemic review and meta-analysis.BMC gastroenterology · 2019Pooled it
- Association between polymorphisms in the serotonin transporter gene-linked polymorphic region and risk for irritable bowel syndrome in China: evidence based on a meta-analysis.The Journal of international medical research · 2019Pooled it
- The Impact of 5-HTTLPR Polymorphism on Depression and Lymphocyte Changes in Colorectal Cancer Patients Undergoing FOLFOX Chemotherapy.Psychiatry investigation · 2026Article
- Tenapanor is associated with earlier and sustained symptom relief in IBS-C: a post hoc analysis.Therapeutic advances in gastroenterology · 2026Article
- Unraveling the Pathophysiology of Irritable Bowel Syndrome: Mechanisms and Insights.International journal of molecular sciences · 2025Review
- Review
- Pharmacogenetics in IBS: update and impact of GWAS studies in drug targets and metabolism.Expert opinion on drug metabolism & toxicology · 2024Review
- The Associations of Single Nucleotide Polymorphisms with Risk and Symptoms of Irritable Bowel Syndrome.Journal of personalized medicine · 2022Article
- Article
- Impact of serotonin transporter gene polymorphism on gut motility in patients with type 2 Diabetes mellitus.Journal of neurogastroenterology and motility · 2021Article
- International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function.Pharmacological reviews · 2021Review
- IBS-Symptoms in IBD Patients-Manifestation of Concomitant or Different Entities.Journal of clinical medicine · 2020Review
- Second Asian Consensus on Irritable Bowel Syndrome.Journal of neurogastroenterology and motility · 2019Review
- Expression of tryptophan hydroxylase in gastric mucosa in symptomatic and asymptomaticArchives of medical science : AMS · 2019Article
- Association of polymorphic variants in serotonin re-uptake transporter gene with Crohn's disease: a retrospective case-control study.Croatian medical journal · 2018Article
- Acupuncture for irritable bowel syndrome: study protocol for a multicenter randomized controlled trial.Trials · 2018Article
- Effect ofWorld journal of gastroenterology · 2018Article
- Pharmacogenetics and the treatment of functional gastrointestinal disorders.Pharmacogenomics · 2017Review
- Role of mast cell-miR-490-5p in irritable bowel syndrome.World journal of gastroenterology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe results of previous studies assessing the association between the 5-HTTLPR polymorphism of serotonin transporter gene and irritable bowel syndrome (IBS) are inconsistent. The aim of this study was to clarify the association between the 5-HTTLPR mutation and the presence of IBS and its subtypes with a meta-analysis of 25 studies.
methodsA thorough search for case-control studies evaluating the association between the 5-HTTLPR polymorphism of serotonin transporter gene and the presence of IBS was carried out in four electronic databases. A meta-analysis was performed in accordance with the Cochrane Handbook for systemic reviews.
resultsA total of 25 articles with 3443 IBS cases and 3359 controls were included into our meta-analysis. No significant association was found between this polymorphism and IBS in all populations. Whereas the LL genotype was demonstrated to be a risk factor for constipation predominant IBS (IBS-C) development in the overall population (LL vs SS: OR = 1.570, 95% CI = 1.147-2.148, P = 0.005, Bon = 0.030; LL vs LS: OR = 1.658, 95% CI = 1.180-2.331, P = 0.004, Bon = 0.024; LL vs LS/SS: OR = 1.545, 95% CI = 1.187-2.012, P = 0.001, Bon = 0.006). In the analysis of different ethnicities, L allele and LL genotype were significantly associated with increased IBS-C risk in the East Asian population (L vs S: OR = 1.487, 95% CI = 1.139-1.941, P = 0.003, Bon = 0.018; LL vs SS: OR = 2.575, 95% CI = 1.741-3.808, P = 0.000, Bon = 0.000; LL vs LS: OR = 3.084, 95% CI = 2.017-4.715, P = 0.000, Bon = 0.000; LL vs LS/SS: OR = 2.759, 95% CI = 1.933-3.938, P = 0.000, Bon = 0.000), but not in the Caucasian population.
conclusionsDifferent from the conclusions of the earlier meta-analyses, the 5-HTTLPR mutation affects IBS-C but not IBS-D and IBS-M development and this effect only exists in the East Asian population but not other populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.